Percutaneous coronary intervention (PCI) utilizing drug-eluting stents is becoming a very common revascularization technique in the dialysis cohort; therefore, we sought to identify the impact of dialysis on outcomes in this group of patients. This is a multicenter registry comparing results of 290 patients (186 with normal kidney function, 104 on dialysis) who underwent PCI with exclusive use of paclitaxel-eluting TAXUS stent. The primary endpoint was an assessment of major adverse cardiac events (MACE) at 1- and 2-year observation. Mean follow-up was 23.3±6.1 months. Results at 12 months showed: MACE 11.8% vs. 7.7% (P=not significant [ns]), composite major adverse cardiac and cerebrovascular events (MACCE) 12.4% vs. 11.5% (P=ns), all-cause death 2.7% vs. 8.6% (P<0.05), cardiac death 2.7% vs. 1.9% (P=ns), target vessel revascularization (TVR) 9.1% vs. 6.7% (P=ns), acute myocardial infarction (AMI) 3.8% vs. 2.9% (P=ns), cerebrovascular events (CVA) 0.5% vs. 1.0% (P=ns); and results at 24 months showed: MACE 17.7% vs. 18.3% (P=ns), MACCE 21.5% vs. 26.0% (P=ns), all-cause death 4.3% vs. 14.4% (P<0.01), cardiac death 3.2% vs. 1.9% (P=ns), TVR 14.0% vs. 16.3% (P=ns), AMI 5.4% vs. 5.8% (P=ns), CVA 3.2% vs. 2.9% (P=ns) for non-end-stage renal disease (ESRD) and dialysis group, respectively. Prior coronary artery bypass graft (CABG) was found to be single risk factor for MACE, TVR, and MACCE in patients with ESRD, while dialysis and prior CABG were found to be single risk factors for death in the entire population. PCI with TAXUS is a feasible procedure and presents promising results in dialysis-dependent patients.
- Drug-eluting stents
- End-stage renal disease
- Percutaneous coronary intervention
ASJC Scopus subject areas